Carlos Pelayo Hernández-Fernández, Gregorio Carretero, Raquel Rivera, Carlos Ferrándiz, Esteban Daudén, Pablo de la Cueva, Isabel Belinchón, Francisco Javier Gómez-García, Enrique Herrera-Acosta, Diana P. Ruiz-Genao, Marta Ferrán, Mercé Alsina, Ofelia Baniandrés-Rodríguez, José Luis Sánchez-Carazo, Rafael Botella-Estrada, Antonio Sahuquillo-Torralba, Lourdes Rodríguez, Jaime Vilar-Alejo, Carmen García-Donoso, José M. Carrascosa, Mar Llamas-Velasco, Enrique Herrera-Ceballos, Jose Luis López-Estebaranz, Conrad Pujol-Marco, Miguel Angel Descalzo, Ignacio Garcia-Doval,, the BIOBADADERM Study Group
DOI: 10.2340/00015555-3711

The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.

The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to determine, in a large group of 2,881 patients followed from January 2008 to November 2018, whether sex influences prescription, effectiveness of therapy, or the risk of adverse events. The results show that women were more likely than men to be prescribed systemic therapy. No differences between men and women were found in the effectiveness of therapy. Women were also more likely to experience adverse events, but the difference in risk is small, and does not justify different management.

Table SI
Table SII
Table SIII